Thyroid hormone analogues: Where do we stand in 2013?

Thyroid

Volumn 23, Issue 11, 2013, Pages 1333-1344

  Meruvu, Sunitha ^a   Ayers, Stephen D ^a   Winnier, Glenn ^a   Webb, Paul ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 DIBROMO 3' (2,3 DIHYDRO 3 OXO 6 PYRIDAZINYLMETHYL)THYRONINE; 3,5 DIIODOTHYROPROPIONIC ACID; CGH 509A; CGS 23425; CHOLESTEROL; EPROTIROME; GC 24; HORMONE RECEPTOR AFFECTING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KB 141; LIOTHYRONINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MB 07344; MB 07811; PLACEBO; SELECTIVE THYROID HORMONE MODULATOR; SOBETIROME; THYROID HORMONE; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; THYROXINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

BASAL METABOLIC RATE; BLOOD PRESSURE; BODY FAT; CARTILAGE INJURY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DNA RESPONSIVE ELEMENT; DRUG CONJUGATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FATIGUE; FIRST PASS EFFECT; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GLUCONEOGENESIS; GLUCOSE METABOLISM; HEART RATE; HEART RHYTHM; HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPERCHOLESTEROLEMIA; LIGAND BINDING; LIPID METABOLISM; LIVER TOXICITY; LOW DRUG DOSE; METABOLIC SYNDROME X; NEGATIVE FEEDBACK; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TEMPERATURE; THERMOGENESIS; THYROID FOLLICLE CELL; THYROID HORMONE SYNTHESIS; TISSUE DISTRIBUTION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTITHYROID AGENTS; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; FATTY LIVER; GLUCOSE; HOMEOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; METABOLIC SYNDROME X; OBESITY; RECEPTORS, THYROID HORMONE; SIGNAL TRANSDUCTION; THYROID HORMONE RECEPTORS BETA; THYROID HORMONES;

EID: 84887462174     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0458     Document Type: Review

References (110)

1. Ford ES, Giles WH, Dietz WH 2002 Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356-359. (Pubitemid 34251969)
2. Baxter JD, Webb P 2009 Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 8:308-320.
3. Shoemaker TJ, Kono T, Mariash CN, Evans-Molina C 2012 Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs Endocr Pract 18:954-64.
4. Yen PM 2001 Physiological and molecular basis of thyroid hormone action. Physiol Rev 81:1097-1142. (Pubitemid 32606667)
5. Brent GA 2012 Mechanisms of thyroid hormone action. J Clin Invest 122:3035-3043.
6. Forrest D 2004 The developing brain and maternal thyroid hormone: finding the links. Endocrinology 145:4034-4036. (Pubitemid 39120548)
7. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD, Klein RZ 1999 Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 341:549-555. (Pubitemid 29384162)
8. Lazarus JH, Bestwick JP, Channon S, Paradice R, Maina A, Rees R, Chiusano E, John R, Guaraldo V, George LM, Perona M, Dall'Amico D, Parkes AB, Joomun M, Wald NJ 2012 Antenatal thyroid screening and childhood cognitive function. N Engl J Med 366:493-501.
9. Brent GA 2012 The debate over thyroid-function screening in pregnancy. N Engl J Med 366:562-563.
10. Mason RL, Hunt HM, Hurxthal L 1930 Blood cholesterol values in hyperthyroidism and hypothyroidism-their significance. N Engl J Med 203:1273-1278.
11. Boyd GS, Oliver MF 1960 The effect of certain thyroxine analogues on the serum lipids in human subjects. Endocrinology 21:33-43.
12. Simpkins S 1937 Dinitrophenol and dessicated thyroid in the treatment of obesity. JAMA 108:2110-2119.
13. The Coronary Drug Project Research Group 1972 The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group. JAMA 220:996-1008.
14. Chiamolera MI, Wondisford FE 2009 Minireview: thyrotropin-releasing hormone and the thyroid hormone feedback mechanism. Endocrinology 150:1091-1096.
15. St Germain DL, Hernandez A, Schneider MJ, Galton VA 2005 Insights into the role of deiodinases from studies of genetically modified animals. Thyroid 15:905-916. (Pubitemid 41339269)
16. Arrojo E Drigo R, Fonseca TL, Werneck-de-Castro JP, Bianco AC 2013 Role of the type 2 iodothyronine deiodinase (D2) in the control of thyroid hormone signaling. Biochim Biophys Acta 1830:3956-3964.
17. Williams GR, Bassett JH 2011 Deiodinases: the balance of thyroid hormone: local control of thyroid hormone action: role of type 2 deiodinase. J Endocrinol 209:261-272.
18. Visser WE, Friesema EC, Visser TJ 2011 Minireview: thyroid hormone transporters: the knowns and the unknowns. Mol Endocrinol 25:1-14.
19. Suzuki S, Mori J, Hashizume K 2007 mu-crystallin, a NADPH-dependent T(3)-binding protein in cytosol. Trends Endocrinol Metab 18:286-289. (Pubitemid 47332215)
20. Scanlan TS, Suchland KL, Hart ME, Chiellini G, Huang Y, Kruzich PJ, Frascarelli S, Crossley DA, Bunzow JR, Ronca-Testoni S, Lin ET, Hatton D, Zucchi R, Grandy DK 2004 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 10:638-642. (Pubitemid 38796856)
21. Ianculescu AG, Scanlan TS 2010 3-Iodothyronamine (T(1)AM): a new chapter of thyroid hormone endocrinology Mol Biosyst 6:1338-1344.
22. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J 2006 Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:484-489. (Pubitemid 43152840)
23. O'Shea PJ, Williams GR 2002 Insight into the physiological actions of thyroid hormone receptors from genetically modified mice. J Endocrinol 175:553-570. (Pubitemid 36054228)
24. Wagner RL, Huber BR, Shiau AK, Kelly A, Cunha Lima ST, Scanlan TS, Apriletti JW, Baxter JD, West BL, Fletterick RJ 2001 Hormone selectivity in thyroid hormone receptors. Mol Endocrinol 15:398-410. (Pubitemid 32221917)
25. Glass CK, Rosenfeld MG 2000 The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14:121-141. (Pubitemid 30070977)
26. Cheng SY, Leonard JL, Davis PJ 2010 Molecular aspects of thyroid hormone actions. Endocr Rev 31:139-170.
27. Zhang J, Lazar MA 2000 The mechanism of action of thyroid hormone. Annu Rev Physiol 62:439-466.
28. Yen PM 2003 Molecular basis of resistance to thyroid hormone. Trends Endocrinol Metab 14:327-333. (Pubitemid 37093130)
29. Weiss RE, Korcarz C, Chassande O, Cua K, Sadow PM, Koo E, Samarut J, Lang R 2002 Thyroid hormone and cardiac function in mice deficient in thyroid hormone receptor-alpha or-beta: an echocardiograph study. Am J Physiol Endocrinol Metab 283:E428-E435. (Pubitemid 35230479)
30. Forrest D, Vennstrom B 2000 Functions of thyroid hormone receptors in mice. Thyroid 10:41-52. (Pubitemid 30090364)
31. Flores-Morales A, Gullberg H, Fernandez L, Stahlberg N, Lee NH, Vennström B, Norstedt G 2002 Patterns of liver gene expression governed by TRbeta. Mol Endocrinol 16:1257-1268. (Pubitemid 34621074)
32. Gullberg H, Rudling M, Saltó C, Forrest D, Angelin B, Vennström B 2002 Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice. Mol Endocrinol 16:1767-1777. (Pubitemid 34828087)
33. Wikström L, Johansson C, Saltó C, Barlow C, Campos Barros A, Baas F, Forrest D, Thorén P, Vennström B 1998 Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1. EMBO J 17:455-461. (Pubitemid 28045486)
34. Gloss B, Trost S, Bluhm W, Swanson E, Clark R, Winkfein R, Janzen K, Giles W, Chassande O, Samarut J, Dillmann W 2001 Cardiac ion channel expression and contractile function in mice with deletion of thyroid hormone receptor alpha or beta. Endocrinology 142:544-550. (Pubitemid 32222402)
35. Weiss RE, Murata Y, Cua K, Hayashi Y, Seo H, Refetoff S 1998 Thyroid hormone action on liver, heart, and energy expenditure in thyroid hormone receptor beta-deficient mice. Endocrinology 139:4945-4952. (Pubitemid 28533441)
36. Grover GJ, Mellström K, Ye L, Malm J, Li YL, Bladh LG, Sleph PG, Smith MA, George R, Vennström B, Mookhtiar K, Horvath R, Speelman J, Egan D, Baxter JD 2003 Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci USA 100:10067-10072. (Pubitemid 37098262)
37. Rubio A, Raasmaja A, Silva JE 1995 Thyroid hormone and norepinephrine signaling in brown adipose tissue. II: Differential effects of thyroid hormone on beta 3-adrenergic receptors in brown and white adipose tissue. Endocrinology 136:3277-3284.
38. Rubio A, Raasmaja A, Maia AL, Kim KR, Silva JE 1995 Effects of thyroid hormone on norepinephrine signaling in brown adipose tissue. I. Beta 1-and beta 2-adrenergic receptors and cyclic adenosine 3¢,5¢-monophosphate generation. Endocrinology 136:3267-3276.
39. Ribeiro MO, Bianco SD, Kaneshige M, Schultz JJ, Cheng SY, Bianco AC, Brent GA 2010 Expression of uncoupling protein 1 in mouse brown adipose tissue is thyroid hormone receptor-beta isoform specific and required for adaptive thermogenesis. Endocrinology 151:432-440.
40. Enerbäck S, Jacobsson A, Simpson EM, Guerra C, Yamashita H, Harper ME, Kozak LP 1997 Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese. Nature 387:90-94. (Pubitemid 27202655)
41. Johansson C, Vennström B, Thorén P 1998 Evidence that decreased heart rate in thyroid hormone receptor-alpha1-deficient mice is an intrinsic defect. Am J Physiol 275(2 Pt 2):R640-646.
42. Chiellini G, Apriletti JW, Yoshihara HA, Baxter JD, Ribeiro RC, Scanlan TS 1998A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol 5:299-306. (Pubitemid 28309983)
43. Bassett JH, Williams GR 2009 The skeletal phenotypes of TRalpha and TRbeta mutant mice. J Mol Endocrinol 42:269-282.
44. Bassett JH, Williams AJ, Murphy E, Boyde A, Howell PG, Swinhoe R, Archanco M, Flamant F, Samarut J, Costagliola S, Vassart G, Weiss RE, Refetoff S, Williams GR 2008A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism. Mol Endocrinol 22:501-512. (Pubitemid 351185945)
45. Bochukova E, Schoenmakers N, Agostini M, Schoenmakers E, Rajanayagam O, Keogh JM, Henning E, Reinemund J, Gevers E, Sarri M, Downes K, Offiah A, Albanese A, Halsall D, Schwabe JW, Bain M, Lindley K, Muntoni F, Vargha-Khadem F, Dattani M, Farooqi IS, Gurnell M, Chatterjee K 2012A mutation in the thyroid hormone receptor alpha gene. N Engl J Med 366:243-249.
46. van Mullem A, van Heerebeek R, Chrysis D, Visser E, Medici M, Andrikoula M, Tsatsoulis A, Peeters R, Visser TJ 2012 Clinical phenotype and mutant TRa1. N Engl J Med 366:1451-1453.
47. Webb P 2004 Selective activators of thyroid hormone receptors. Expert Opin Investig Drugs 13:489-500. (Pubitemid 38714384)
48. Ichikawa K, Miyamoto T, Kakizawa T, Suzuki S, Kaneko A, Mori J, Hara M, Kumagai M, Takeda T, Hashizume K 2000 Mechanismof liver-selective thyromimetic activity ofSK&F L-94901: evidence for the presence of a cell-type-specific nuclear iodothyronine transport process. J Endocrinol 165:391-397. (Pubitemid 30341088)
49. Taylor AH, Stephan ZF, Steele RE, Wong NC 1997 Beneficial effects of a novel thyromimetic on lipoprotein metabolism. Mol Pharmacol 52:542-547. (Pubitemid 27412981)
50. Moreno M, de Lange P, Lombardi A, Silvestri E, Lanni A, Goglia F 2008 Metabolic effects of thyroid hormone derivatives. Thyroid 18:239-253. (Pubitemid 351271526)
51. Stephan ZF, Yurachek EC, Sharif R, Wasvary JM, Steele RE, Howes C 1992 Reduction of cardiovascular and thyroxinesuppressing activities of L-T3 by liver targeting with cholic acid. Biochem Pharmacol 43:1969-1974.
52. Chiellini G, Apriletti JW, Yoshihara HA, Baxter JD, Ribeiro RC, Scanlan TS 1998A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol 5:299-306. (Pubitemid 28309983)
53. Borngraeber S, Budny MJ, Chiellini G, Cunha-Lima ST, Togashi M, Webb P, Baxter JD, Scanlan TS, Fletterick RJ 2003 Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc Natl Acad Sci USA 100:15358-15363. (Pubitemid 38020994)
54. Grover GJ, Mellstrom K, Malm J 2005 Development of the thyroid hormone receptor beta-subtype agonist KB-141: a strategy for body weight reduction and lipid lowering with minimal cardiac side effects. Cardiovasc Drug Rev 23:133-148. (Pubitemid 41278972)
55. Berkenstam A, Kristensen J, Mellström K, Carlsson B, Malm J, Rehnmark S, Garg N, Andersson CM, Rudling M, Sjöberg F, Angelin B, Baxter JD 2008 The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 105:663-667. (Pubitemid 351171765)
56. Apriletti JW, Ribeiro RC,Wagner RL, FengW,Webb P, Kushner PJ, West BL,Nilsson S, Scanlan TS, Fletterick RJ, Baxter JD 1998 Molecular and structural biology of thyroid hormone receptors. Clin Exp Pharmacol Physiol Suppl 25:S2-11.
57. Bleicher L, Aparicio R, Nunes FM, Martinez L, Gomes Dias SM, Figueira AC, Santos MA, Venturelli WH, da Silva R, Donate PM, Neves FA, Simeoni LA, Baxter JD, Webb P, Skaf MS, Polikarpov I 2008 Structural basis of GC-1 selectivity for thyroid hormone receptor isoforms. BMC Struct Biol 8:8.
58. Yoshihara HA, Apriletti JW, Baxter JD, Scanlan TS 2003 Structural determinants of selective thyromimetics. J Med Chem 46:3152-3161. (Pubitemid 36775935)
59. Togashi M, Borngraeber S, Sandler B, Fletterick RJ, Webb P, Baxter JD 2005 Conformational adaptation of nuclear receptor ligand binding domains to agonists: potential for novel approaches to ligand design. J Steroid Biochem Mol Biol 93:127-137. (Pubitemid 40602485)
60. Nascimento AS, Dias SM, Nunes FM, Apaŕcio R, Ambrosio AL, Bleicher L, Figueira AC, Santos MA, de Oliveira Neto M, Fischer H, Togashi M, Craievich AF, Garratt RC, Baxter JD, Webb P, Polikarpov I 2006 Structural rearrangements in the thyroid hormone receptor hinge domain and their putative role in the receptor function. J Mol Biol 360:586-598. (Pubitemid 43975107)
61. Mart́nez L, Nascimento AS, Nunes FM, Phillips K, Aparicio R, Dias SM, Figueira AC, Lin JH, Nguyen P, Apriletti JW, Neves FA, Baxter JD, Webb P, Skaf MS, Polikarpov I 2009 Gaining ligand selectivity in thyroid hormone receptors via entropy. Proc Natl Acad Sci USA 106:20717-20722.
62. Ocasio CA, Scanlan TS 2008 Characterization of thyroid hormone receptor alpha (TRalpha)-specific analogs with varying inner-and outer-ring substituents. Bioorg Med Chem 16:762-770. (Pubitemid 351163068)
63. Grijota-Mart́nez C, Samarut E, Scanlan TS, Morte B, Bernal J 2011 In vivo activity of the thyroid hormone receptor beta-and a-selective agonists GC-24 and CO23 on rat liver, heart, and brain. Endocrinology 152:1136-1142.
64. Nguyen NH, Apriletti JW, Cunha Lima ST, Webb P, Baxter JD, Scanlan TS 2002 Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J Med Chem 45:3310-3320. (Pubitemid 34774281)
65. Nguyen NH, Apriletti JW, Baxter JD, Scanlan TS 2005 Hammett analysis of selective thyroid hormone receptor modulators reveals structural and electronic requirements for hormone antagonists. J Am Chem Soc 127:4599-4608. (Pubitemid 40489616)
66. Baxter JD, Goede P, Apriletti JW, West BL, Feng W, Mellstrom K, Fletterick RJ, Wagner RL, Kushner PJ, Ribeiro RC, Webb P, Scanlan TS, Nilsson S 2002 Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. Endocrinology 143:517-524. (Pubitemid 34107205)
67. Lim W, Nguyen NH, Yang HY, Scanlan TS, Furlow JD 2002A thyroid hormone antagonist that inhibits thyroid hormone action in vivo. J Biol Chem 277:35664-35670.
68. MalmJ,FärnegârdhM,GroverGJ,LadensonPW2009Thyroid hormone antagonists: potential medical applications and structureactivityrelationships. CurrMedChem16:3258-3266.
69. Erion MD, Cable EE, Ito BR, Jiang H, Fujitaki JM, Finn PD, Zhang BH, Hou J, Boyer SH, van Poelje PD, Linemeyer DL 2007 Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci USA 104:15490-15495. (Pubitemid 47502944)
70. Fujitaki JM, Cable EE, Ito BR, Zhang BH, Hou J, Yang C, Bullough DA, Ferrero JL, van Poelje PD, Linemeyer DL, Erion MD 2008 Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist. Drug Metab Dispos 36:2393-2403.
71. Yuan C, Lin JZ, Sieglaff DH, Ayers SD, Denoto-Reynolds F, Baxter JD, Webb P 2012 Identical gene regulation patterns of T3 and selective thyroid hormone receptor modulator GC-1. Endocrinology 153:501-511.
72. Yen PM, Feng X, Flamant F, Chen Y, Walker RL, Weiss RE, Chassande O, Samarut J, Refetoff S, Meltzer PS 2003 Effects of ligand and thyroid hormone receptor isoforms on hepatic gene expression profiles of thyroid hormone receptor knockout mice. EMBO Rep 4:581-587. (Pubitemid 36939949)
73. Chan IH, Privalsky ML 2009 Isoform-specific transcriptional activity of overlapping target genes that respond to thyroid hormone receptors alpha1 and beta1. Mol Endocrinol 23:1758-1775.
74. Pramfalk C, Pedrelli M, Parini P 2011 Role of thyroid receptor beta in lipid metabolism. Biochim Biophys Acta 1812:929-937.
75. Tancevski I, Demetz E, Eller P 2011 Sobetirome: a selective thyromimetic for the treatment of dyslipidemia. Recent Pat Cardiovasc Drug Discov 6:16-19.
76. Bryzgalova G, Effendic S, Khan A, Rehnmark S, Barbounis P, Boulet J, Dong G, Singh R, Shapses S, Malm J, Webb P, Baxter JD, Grover GJ 2008 Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. J Steroid Biochem Mol Biol 111:262-267.
77. Tancevski I, Demetz E, Eller P, Duwensee K, Hoefer J, Heim C, Stanzl U, Wehinger A, Auer K, Karer R, Huber J, Schgoer W, Van Eck M, Vanhoutte J, Fievet C, Stellaard F, Rudling M, Patsch JR, Ritsch A 2010 The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice. PloS One 5:e8722.
78. Tancevski I, Wehinger A, Demetz E, Hoefer J, Eller P, Huber E, Stanzl U, Duwensee K, Auer K, Schgoer W, Kuhn V, Fievet C, Stellaard F, Rudling M, Foeger B, Patsch JR, Ritsch A 2009 The thyromimetic T-0681 protects from atherosclerosis. J. Lipid Res 50:938-944.
79. Gullberg H, Rudling M, Forrest D, Angelin B, Vennström B 2000 Thyroid hormone receptor beta-deficient mice show complete loss of the normal cholesterol 7 alpha-hydroxylase (CYP7A) response to thyroid hormone but display enhanced resistancetodietarycholesterol.MolEndocrinol14:1739-1749.
80. Poli A 2007 Atorvastatin: pharmacological characteristics and lipid-lowering effects. Drugs 67(Suppl 1):3-15.
81. Ito BR, Zhang BH, Cable EE, Song X, Fujitaki JM, MacKenna DA, Wilker CE, Chi B, van Poelje PD, Linemeyer DL, Erion MD 2009 Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Br J Pharmacol 156:454-465.
82. Lin JZ, Martagón AJ, Hsueh WA, Baxter JD, Gustafsson JA° , Webb P, Phillips KJ 2012 Thyroid hormone receptor agonists reduce serum cholesterol independent of the LDL receptor. Endocrinology 153:6136-6144.
83. Goldberg IJ, Huang LS, Huggins LA, Yu S, Nagareddy PR, Scanlan TS, Ehrenkranz JR 2012 Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway. Endocrinology 153:5143-5149.
84. Hargrove GM, Junco A, Wong NC 1999 Hormonal regulation of apolipoprotein A1. J Mol Endocrinol 22:103-111.
85. Pedrelli M, Pramfalk C, Parini P 2010 Thyroid hormones and thyroid hormone receptors: effects of thyromimetics on reverse cholesterol transport. World J Gastroenterol 16: 5958-5964.
86. Trost SU, Swanson E, Gloss B, Wang-Iverson DB, Zhang H, Volodarsky T, Grover GJ, Baxter JD, Chiellini G, Scanlan TS, Dillmann WH 2000 The thyroid hormone receptor-betaselective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 141:3057-3064. (Pubitemid 32268991)
87. Grover GJ, Egan DM, Sleph PG, Beehler BC, Chiellini G, Nguyen NH, Baxter JD, Scanlan TS 2004 Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3¢-triiodo-L-thyronine. Endocrinology 145:1656-1661. (Pubitemid 38402372)
88. Villicev CM, Freitas FR, Aoki MS, Taffarel C, Scanlan TS, Moriscot AS, Ribeiro MO, Bianco AC, Gouveia CH 2007 Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats. J Endocrinol 193:21-29. (Pubitemid 46638528)
89. Miyabara EH, Aoki MS, Soares AG, Saltao RM, Vilicev CM, Passarelli M, Scanlan TS, Gouveia CH, Moriscot AS 2005 Thyroid hormone receptor-beta-selective agonist GC-24 spares skeletal muscle type I to II fiber shift. Cell Tissue Res 321:233-241. (Pubitemid 41127030)
90. Freitas FR, Capelo LP, O'Shea PJ, Jorgetti V, Moriscot AS, Scanlan TS, Williams GR, Zorn TM, Gouveia CH 2005 The thyroid hormone receptor beta-specific agonist GC-1 selectively affects the bone development of hypothyroid rats. J Bone Miner Res 20:294-304.
91. Amorim BS, Ueta CB, Freitas BC, Nassif RJ, Gouveia CH, Christoffolete MA, Moriscot AS, Lancelloti CL, Llimona F, Barbeiro HV, de Souza HP, Catanozi S, Passarelli M, Aoki MS, Bianco AC, Ribeiro MO 2009A TRbeta-selective agonist confers resistance to diet-induced obesity. J Endocrinol 203:291-299.
92. Wu J, Cohen P, Spiegelman BM 2013 Adaptive thermogenesis in adipocytes: is beige the new brown Genes Dev 27:234-250.
93. Lee JY, Takahashi N, Yasubuchi M, Kim YI, Hashizaki H, Kim MJ, Sakamoto T, Goto T, Kawada T 2012 Triiodothyronine induces UCP-1 expression and mitochondrial biogenesis in human adipocytes. Am J Physiol Cell Physiol 302:C463-472.
94. Crunkhorn S, Patti ME 2008 Links between thyroid hormone action, oxidative metabolism, and diabetes risk Thyroid 18:227-237. (Pubitemid 351271527)
95. Cannon B, Nedergaard J 2011 Nonshivering thermogenesis and its adequate measurement in metabolic studies. J Exp Biol 214(Pt 2):242-253.
96. Perra A, Simbula G, Simbula M, Pibiri M, Kowalik MA, Sulas P, Cocco MT, Ledda-Columbano GM, Columbano A 2008 Thyroid hormone (T3) and TR beta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats. FASEB J 22:2981-2989.
97. Cable EE, Finn PD, Stebbins JW, Hou J, Ito BR, van Poelje PD, Linemeyer DL, ErionMD 2009 Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 49:407-417.
98. Sinha RA, You SH, Zhou J, Siddique MM, Bay BH, Zhu X, Privalsky ML, Cheng SY, Stevens RD, Summers SA, Newgard CB, Lazar MA, Yen PM 2012 Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. J Clin Invest 122:2428-2438.
99. Targher G, Byrne CD 2013 Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 98:483-495.
100. Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, Baxter JD, Angelin B 2010 Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 362:906-916.
101. Lin V, Klepp H, Hanley R 2008 Sobetirome is a thyroid hormone receptor beta and liver selective thyromimetic that can effect substantial LDL-C lowering without significant changes in heart rate or the thyroid axis in euthyroid men. 90th Annual Meeting of the Endocrine Society, OR36-OR33.
102. Goldman S,McCarrenM,Morkin E, Ladenson PW, Edson R, Warren S, Ohm J, Thai H, Churby L, Barnhill J, O'Brien T, Anand I,Warner A,Hattler B, Dunlap M, Erikson J, ShihMC, Lavori P 2009 DITPA (3,5-Diiodothyropropionic Acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study. Circulation 119:3093-3100.
103. Ladenson PW, McCarren M, Morkin E, Edson RG, Shih MC, Warren SR, Barnhill JG, Churby L, Thai H, O'Brien T, Anand I, Warner A, Hattler B, Dunlap M, Erikson J, Goldman S 2010 Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study. J Clin Endocrinol Metab 95:1349-1354.
104. Waung JA, Bassett JH, Williams GR 2012 Thyroid hormone metabolism in skeletal development and adult bone maintenance. Trends Endocrinol Metab 23:155-162.
105. McLean RM, Podell DN 1995 Bone and joint manifestations of hypothyroidism. Semin Arthritis Rheum 24:282-290.
106. Goldberg AC 2010 Novel therapies and new targets of treatment for familial hypercholesterolemia. J Clin Lipidol 4:350-356.
107. Berger J, Pujol A, Aubourg P, Forss-Petter S 2010 Current and future pharmacological treatment strategies in Xlinked adrenoleukodystrophy. Brain Pathol 20:845-856.
108. Abohashem-Aly AA, Meng X, Li J, Sadaria MR, Ao L, Wennergren J, Fullerton DA, Raeburn CD 2011 DITPA, a thyroid hormone analog, reduces infarct size and attenuates the inflammatory response following myocardial ischemia. J Surg Res 171:379-385.
109. Guran T, Turan S, Bircan R, Bereket A 2009 9 years followup of a patient with pituitary form of resistance to thyroid hormones (PRTH): comparison of two treatment periods of D-thyroxine and triiodothyroacetic acid (TRIAC). J Pediatr Endocrinol Metab 22:971-978.
110. Di Cosmo C, Liao XH, Dumitrescu AM, Weiss RE, Refetoff S 2009A thyroid hormone analog with reduced dependence on the monocarboxylate transporter 8 for tissue transport. Endocrinology 150:4450-4458.